Quick Answer
Unicycive Therapeutics, Inc. reported Net Income of -$26.55 million for fiscal year 2025.
Unicycive Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$26.55M | +27.7% |
| 2024 | -$36.73M | -20.2% |
| 2023 | -$30.54M | -69.1% |
| 2022 | -$18.06M | -80.3% |
| 2021 | -$10.02M | -342.4% |
| 2020 | -$2.26M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.01M | -46.8% | +6.8% |
| June 30, 2025 | -$6.45M | -165.4% | -1231.1% |
| March 31, 2025 | $570.0K | +102.7% | +113.9% |
| September 30, 2024 | -$4.10M | +5.5% | -141.6% |
| June 30, 2024 | $9.86M | +356.8% | +147.0% |
| March 31, 2024 | -$20.96M | -43.8% | -383.8% |
| September 30, 2023 | -$4.33M | +22.0% | -12.9% |
| June 30, 2023 | -$3.84M | -5.6% | +73.7% |
- Unicycive Therapeutics, Inc. showed an increase of +27.7% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Unicycive Therapeutics, Inc.’s net income has declined by 1072.9% (from -$2.26 million to -$26.55 million).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: